Global HPV Testing and PAP Test Market is expected to grow at a Healthy CAGR of 12-15 % from 2022 to 2027
Cervical cancer is a malignant tumor that Starts in the cells of the cervix, the lowermost part of the uterus. Cervical cancer begins when the cells on its surface transform into precancerous cells. If not destroyed or removed, these abnormal cells may turn into cancer cells and spread in the cervix and surrounding areas. HPV and PAP tests are Included in Cervical cancer screening, which can identify early-stage HPV infection or pre-cancerous abnormalities. By offering timely treatment, the onset of cancer can be prevented.
Slowdown in the HPV
Testing and PAP Test Market due to Covid-19
The Covid-19 pandemic
has impacted the healthcare sector in several aspects. During the pandemic owing
to social-distancing norms in hospitals and clinics, there was a delay in
various diagnostic examinations and procedures. The delay in cancer screening
services because of a shortage of staff and disruption in the supply chain of
testing kits across the globe has led to an adverse impact on the HPV Testing
and PAP Test market during the outbreak.
However, in April
2020 amidst the pandemic when all non-emergence procedures halted, in Sweden
HPV sampling kits were distributed among the eligible group of Females across
the country.
“When everything
stopped, we had to think of something completely different. The expectation is
that many women will be prevented from developing cervical cancer and that we
will progress faster on the path to reaching the WHO target of elimination of
cervical cancer with the help of these kits.”
-
Cancer Specialist, Research-Led Medical University,
Sweden
Technological
Advancements are Driving the Demand in the Global HPV Testing and PAP Tests Market
The Increasing demand for the development of technologically advanced
screening tests for the early detection of cervical and vaginal cancers is poised
to drive the HPV testing and PAP test market. The global market for HPV testing and PAP tests is also being driven by
the increase in the number of screening campaigns organized by both government
and non-governmental organizations.
For instance,
- In Feb 2023, BD (Becton, Dickinson and Company) announced that U.S. Food and Drug Administration (FDA) approved BD Onclarity™ HPV Assay to be used with the ThinPrep® Pap Test. BD Onclarity™ HPV Assay can individually detect and identify 14 high-risk HPV genotypes in a single analysis
Rising
Cases of Cervical Cancer Boosts HPV Testing and PAP Test Market
The
Rising prevalence of the number of cervical cancers, the growing aging
population and the development of advanced technological screening tests are
the key factors driving the market. Public awareness campaigns initiated by the
government and other organizations, improving health insurance coverage, and favorable
reimbursement policies are some of the other crucial factors driving the demand
for the HPV Testing and PAP Test market globally. For instance,
- In August 2022, Sansure Biotech got approval from NMPA (National Medical Products Administration China), for marketing Human Papillomavirus DNA (23 genotypes) Diagnostic Kit (PCR-Fluorescence Probing) developed using fast nucleic acid release technology and can screen 18 high-risk types and 5 low-risk types genotypes for cervical cancer
Key
Constraints Affecting the growth of HPV Testing and PAP Test Market
The adoption of revised regulatory guidelines for
cervical cancer screening, the availability of HPV vaccination world over, and
the high cost of screening tests in developing nations may hamper the growth of
the HPV Testing and PAP Test market in the coming years.
North
America Accounts for the Largest Share of the HPV Testing and PAP
Test Global Market
North America is projected to dominate the HPV
Testing and PAP Test market. This can be primarily attributed to the rising
number of cervical cancers and awareness programs, favourable reimbursement
policies, the presence of key players, and the developed healthcare system in the region.
However, the Asia-Pacific region is anticipated to grow with the highest CAGR
in the forecast period. Factors such as technological advancements, free
screening programs, and strategic initiatives taken by public and private
organizations are some of the key factors Fuelling the Asia-Pacific market.
Competitive Landscape : HPV Testing and PAP Test Market
The key players operating in the market include Abbott Laboratories, F.
Hoffmann-La Roche AG, Becton, Dickinson and Company, Quest Diagnostics, Hologic
Inc., Femasys Inc., Arbor Vita Corporation, Seegene Inc. and Thermo Fischer
Scientific Inc., among others.
Organic and Inorganic Growth
Strategies Adopted by Players to Gain Ground in the Market
Compnaies operating in this market are Implementing organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share. For instance
- In May 2022, the London School of Hygiene & Tropical Medicine (LSHTM) in partnership with the University of Manchester and University of Hull, initiated the ‘Catch-up Screen’ project which will offer an HPV test to women of aged 65 and above by working with local GP practices. It is expected that approximately 10,000 women will be invited to participate in this project, which will help in evaluating if at-home tests are an effective way to reduce cancer among this older age group. The Yorkshire Cancer Research charity has provided £1.5 million in funding for this project, which is scheduled to commence in April 2023.
The HPV Testing and PAP test market is a growing market that is poised to gain further momentum in the years to come due to a surge in awareness for early diagnosis of cervical cancer, investment in R&D to introduce several advanced screening tests, and aggressive organic and inorganic growth strategies adopted by the players.
Get Detailed Insights on the HPV Testing and PAP Test Market @ https://meditechinsights.com/hpv-testing-and-pap-test-market/
About Medi-Tech Insights
Medi-Tech Insights is a
healthcare-focused business research & insights firm. Our clients
include Fortune 500 companies, blue-chip investors & hyper-growth
start-ups. We have successfully completed 100+ projects in Digital Health,
Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech
Insights
Comments
Post a Comment